Ongoing Projects

 

 

 

 

 

TRINITA’ project

Financed under the Cascade Calls of the NODES Program, supported by the Ministry of University and Research (MUR) through PNRR funds. It falls under the MUR – M4C2 – Investment 1.5 Notice titled “Innovation Ecosystems,” which is part of the PNRR funded by the European Union – NextGenerationEU

Grant agreement Code No. ECS00000036

 

Progetto TRINITA’

Finanziato nell’ambito dei Bandi a Cascata del Programma NODES, sostenuto dal MUR sui fondi PNRR MUR – M4C2 – Investimento 1.5 Avviso “Ecosistemi dell’Innovazione”, nell’ambito del PNRR finanziato dall’Unione europea – NextGenerationEU

Grant agreement Code No. ECS00000036

 

Project Name: Trinità
Funding Line: Line 5 of the PNRR
Lead Organization: Dompé Farmaceutici

Project Objectives

The Trinità project aims to:

  • Develop innovative therapeutic solutions.
  • Implement cutting-edge medical technologies.
  • Promote advanced scientific research.
ViroStatics’ Role

ViroStatics is involved in various aspects of the project, contributing its expertise in biotechnological research and the development of new therapeutic treatments. The company is committed to:

  • Collaborating closely with Dompé Farmaceutici to achieve the project’s goals.
  • Utilizing PNRR funding to accelerate research progress.
  • Contributing to the creation of innovative medical solutions that can improve patients’ quality of life.
Importance of PNRR Funding

The National Recovery and Resilience Plan represents a unique opportunity to support research and development projects in Italy. The funding received for the Trinità project enables ViroStatics to:

  • Expand its research capabilities.
  • Experiment with new technologies and methodologies.
  • Collaborate with excellence partners like Dompé Farmaceutici.

                         

PANVIRIDE project

Project funded under the National Recovery and Resilience Plan (NRRP), Mission 4 Component 2 Investment 1.5 – Cascade Call “One Health Basic and Translational Research Actions addressing Unmet Needs on Emerging Infectious Diseases” COC-1-2023-CNR INF-ACT P00000007, CUP B53C20040570005

Award Number: Cascade Call “One Health Basic and Translational Research Actions addressing Unmet Needs on Emerging Infectious Diseases – Spoke 5” COC-1-2023-CNR

Description of the Project

The PANVIRIDE research program will support the activities of INF-ACT Spoke 5 in addressing the pressing global challenge of emerging viral threats by developing broad-spectrum antivirals (BSAs) capable of inhibiting multiple viruses, with a focus on respiratory and vector-borne viruses. With the ongoing evolution of viruses and their growing pandemic potential, the limitations of available antiviral drugs have become evident. In this frame, PANVIRIDE’s mission is to accelerate the development of new antiviral drug candidates with a broad-spectrum of activity, to tackle current and future outbreaks, or the emergence of drug-resistant viral strains. 

 

Progetto PANVIRIDE

Progetto finanziato nell’ambito del Piano Nazionale di Ripresa e Resilienza (PNRR), Missione 4 Componente 2 Investimento 1.5 – Bando a cascata “One Health Basic and Translational Research Actions addressing Unmet Needs on Emerging Infectious Diseases” COC-1-2023-CNR INF-ACT P00000007, CUP B53C20040570005

Award

Bando a cascata “One Health Basic and Translational Research Actions addressing Unmet Needs on Emerging Infectious Diseases – Spoke 5” COC-1-2023-CNR

Descrizione del Progetto

PANVIRIDE supporterà le attività dello Spoke 5 della Fondazione INF-ACT per affrontare la sfida globale urgente delle minacce virali emergenti sviluppando antivirali ad ampio spettro (BSA) capaci di inibire più virus, con particolare attenzione ai virus respiratori e trasmessi da vettori. Con l’evoluzione continua dei virus e il loro crescente potenziale pandemico, sono emerse le limitazioni degli attuali farmaci antivirali. In questo contesto, la missione di PANVIRIDE è accelerare lo sviluppo di nuovi candidati antivirali ad ampio spettro, per affrontare le epidemie attuali e future, o l’emergere di ceppi virali resistenti ai farmaci.